User menu

Use of botulinum toxins in cancer therapy.

Bibliographic reference Ansiaux, Réginald ; Gallez, Bernard. Use of botulinum toxins in cancer therapy.. In: Expert opinion on investigational drugs, Vol. 16, no. 2, p. 209-18 (2007)
Permanent URL
  1. Ansiaux R., Botulinum Toxin Potentiates Cancer Radiotherapy and Chemotherapy, 10.1158/1078-0432.ccr-05-1222
  2. ROSSETTO, Scientific and therapeutic aspects of botulinum toxin, 3 (2002)
  3. HANSON, Scientific and therapeutic aspects of botulinum toxin, 11 (2002)
  4. Johnson Eric A., Bradshaw Marite, Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective, 10.1016/s0041-0101(01)00157-x
  5. Dressler Dirk, Saberi Fereshte Adib, Barbosa Egberto Reis, Botulinum toxin: mechanisms of action, 10.1590/s0004-282x2005000100035
  6. PANICKER, Neurol. India, 51, 455 (2003)
  7. Johnson Eric A., Clostridial Toxins as Therapeutic Agents: Benefits of Nature's Most Toxic Proteins, 10.1146/annurev.micro.53.1.551
  8. Mahant N., Clouston P.D., Lorentz I.T., The current use of botulinum toxin, 10.1054/jocn.2000.0684
  9. Huang Wilber, Foster Jill A., Rogachefsky Arlene S., Pharmacology of botulinum toxin, 10.1067/mjd.2000.105567
  10. DasGupta Bibhuti R., Sathyamoorthy Venugopal, Purification and amino acid composition of type A botulinum neurotoxin, 10.1016/0041-0101(84)90085-0
  11. DASGUPTA, Infect. Immun, 14, 680 (1976)
  12. SCHIAVO, Physiol. Rev, 80, 717 (2000)
  13. Aoki K. R., Guyer B., Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions, 10.1046/j.1468-1331.2001.00035.x
  14. Simpson Lance L., IDENTIFICATION OF THE MAJOR STEPS IN BOTULINUM TOXIN ACTION, 10.1146/annurev.pharmtox.44.101802.121554
  15. Lacy D. Borden, Tepp William, Cohen Alona C., DasGupta Bibhuti R., Stevens Raymond C., Crystal structure of botulinum neurotoxin type A and implications for toxicity, 10.1038/2338
  16. Swaminathan Subramanyam, Eswaramoorthy Subramaniam, 10.1038/78005
  17. de Paiva Anton, Oliver Dolly J., Light chain of botulinum neurotoxin is active in mammalian motor nerve terminals when delivered via liposomes, 10.1016/0014-5793(90)80836-8
  18. Paiva Anton de, Ashton Anthony C., Foran Patrick, Schiavo Giampetro, Montecucco Cesare, Dolly J. Oliver, Botulinum A Like Type B and Tetanus Toxins Fulfils Criteria for Being a Zinc-Dependent Protease, 10.1111/j.1471-4159.1993.tb07482.x
  19. Raciborska Dorota A., Trimble William S., Charlton Milton P., Presynaptic protein interactionsin vivo: evidence from botulinum A, C, D and E action at frog neuromuscular junction : Botulinum toxins reveal protein interactions, 10.1046/j.1460-9568.1998.00270.x
  20. KALANDAKANOND, J. Pharmacol. Exp. Ther, 296, 749 (2001)
  21. DOLLY, Scientific and therapeutic aspects of botulinum toxin, 91 (2002)
  22. CHEN, Infect. Immun, 65, 1626 (1997)
  23. Dolly J.Oliver, de Paiva Anton, Foran Patrick, Lawrence Gary, Daniels-Holgate Phillipa, Ashton Anthony C., Probing the process of transmitter release with botulinum and tetanus neurotoxins, 10.1006/smns.1994.1020
  24. Ashton Anthony C., de Paiva Anton M., Poulain Bernard, Tauc Ladislav, Dolly J. Oliver, Factors Underlying the Characteristic Inhibition of the Neuronal Release of Transmitters by Tetanus and Various Botulinum Toxins, Botulinum and Tetanus Neurotoxins (1993) ISBN:9781475795448 p.191-213, 10.1007/978-1-4757-9542-4_20
  25. Dolly J. Oliver, Black Jennifer, Williams Richard S., Melling Jack, Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization, 10.1038/307457a0
  26. Black J. D., Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves, 10.1083/jcb.103.2.521
  27. Dong Min, Richards David A., Goodnough Michael C., Tepp William H., Johnson Eric A., Chapman Edwin R., Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells, 10.1083/jcb.200305098
  28. Rummel Andreas, Mahrhold Stefan, Bigalke Hans, Binz Thomas, The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction : Ganglioside binding of botulinum neurotoxins, 10.1046/j.1365-2958.2003.03872.x
  29. Dong M., SV2 Is the Protein Receptor for Botulinum Neurotoxin A, 10.1126/science.1123654
  30. Mahrhold Stefan, Rummel Andreas, Bigalke Hans, Davletov Bazbek, Binz Thomas, The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves, 10.1016/j.febslet.2006.02.074
  31. SIMPSON, J. Pharmacol. Exp. Ther, 224, 135 (1983)
  32. Black J. D., Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis, 10.1083/jcb.103.2.535
  33. Foran Patrick G., Mohammed Nadiem, Lisk Godfrey O., Nagwaney Sharuna, Lawrence Gary W., Johnson Eric, Smith Leonard, Aoki K. Roger, Dolly J. Oliver, Evaluation of the Therapeutic Usefulness of Botulinum Neurotoxin B, C1, E, and F Compared with the Long Lasting Type A : BASIS FOR DISTINCT DURATIONS OF INHIBITION OF EXOCYTOSIS IN CENTRAL NEURONS, 10.1074/jbc.m209821200
  34. Montecucco Cesare, Molgó Jordi, Botulinal neurotoxins: revival of an old killer, 10.1016/j.coph.2004.12.006
  35. Juzans Pascal, Comella Joan X., Molgo Jordi, Faille Lucette, Angaut-Petit Denise, Nerve terminal sprouting in botulinum type-A treated mouse levator auris longus muscle, 10.1016/0960-8966(96)00041-7
  36. de Paiva A., Meunier F. A., Molgo J., Aoki K. R., Dolly J. O., Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals, 10.1073/pnas.96.6.3200
  37. Aoki K.R, A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice, 10.1016/s0041-0101(01)00101-5
  38. VAN DEN BERGH, Adv. Neurol, 78, 231 (1998)
  39. Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, Marttila R J, Lundh H, Gedin S, Westergren I, Richardson A, Dott C, Cohen H, A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport  and Botox  in the treatment of cervical dystonia, 10.1136/jnnp.64.1.6
  40. Sampaio Cristina, Ferreira Joaquim J., Simões Fernanda, Rosas Maria J., Magalhães Marina, Correia Ana P., Bastos-Lima António, Martins Rairnundo, Castro-Caldas Alexandre, DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1, 10.1002/mds.870120627
  41. Tang-Liu Diane D.-S, Aoki K.Roger, Dolly J.Oliver, de Paiva Anton, Houchen Tara L, Chasseaud Leslie F, Webber Colin, Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution, 10.1016/s0041-0101(03)00196-x
  42. Hsu T. S. Jeffrey, Dover Jeffrey S., Arndt Kenneth A., Effect of Volume and Concentration on the Diffusion of Botulinum Exotoxin A, 10.1001/archderm.140.11.1351
  43. Scott Alan B., Botulinum Toxin Injection into Extraocular Muscles as an Alternative to Strabismus Surgery, 10.1016/s0161-6420(80)35127-0
  44. Oates John A., Wood Alastair J.J., Jankovic Joseph, Brin Mitchell F., Therapeutic Uses of Botulinum Toxin, 10.1056/nejm199104253241707
  45. Jankovic Joseph, Brin Mitchell F., Botulinum toxin: Historical perspective and potential new indications, 10.1002/(sici)1097-4598(1997)6+<129::aid-mus9>;2-b
  46. SCOTT, Scientific and therapeutic aspects of botulinum toxin, 3 (2002)
  47. Carruthers Alastair, Botulinum toxin type A: History and current cosmetic use in the upper face, 10.1053/mda.2001.25138
  48. Guo Y., Shin K., Unique use of botulinum toxin to decrease adductor tone and allow surgical excision of vulvar carcinoma, 10.1111/j.1048-891x.2004.014021.x
  49. Lou Jau-Shin, Pleninger Perrin, Kurlan Roger, Botulinum toxin a is effective in treating trismus associated with postradiation myokymia and muscle spasm, 10.1002/mds.870100527
  50. Van Daele Douglas J., Finnegan Eileen M., Rodnitzky Robert L., Zhen Weining, McCulloch Timothy M., Hoffman Henry T., Head and Neck Muscle Spasm After Radiotherapy : Management With Botulinum Toxin A Injection, 10.1001/archotol.128.8.956
  51. De Micheli C., Fornengo P., Bosio A., Epifani G., Pascale C., Severe Radiation-Induced Proctitis Treated With Botulinum Anatoxin Type A, 10.1200/jco.2003.99.030
  52. Lo Nigro Luca, Costantino Francesco, Schilirò Gino, Safe administration of muscle-relaxing botulismotoxin during treatment for leukemia, 10.1002/mpo.1302
  53. Sener Emin Cumhur, Kiratli Hayyam, Gedik Sansal, Sanac Ali Sefik, Ocular motility disturbances after episcleral plaque brachytherapy for uveal melanoma, 10.1016/j.jaapos.2003.09.007
  54. ILHAN, Eur. J. Ophthalmol, 12, 55 (2002)
  55. Birch J.F., Varma S.K., Narula A.A., Botulinum toxoid in the management of gustatory sweating (Frey’s syndrome) after superficial parotidectomy, 10.1054/bjps.1998.3058
  56. Kyrmizakis Dionysios E, Pangalos Aris, Papadakis Chariton E, Logothetis John, Maroudias Nicolas J, Helidonis Emmanuel S, The use of botulinum toxin type A in the treatment of Frey and crocodile tears syndromes, 10.1016/j.joms.2003.09.015
  57. Williamson Lura C., Neale Elaine A., Syntaxin and 25-kDa synaptosomal-associated protein: Differential effects of botulinum neurotoxins C1 and A on neuronal survival, 10.1002/(sici)1097-4547(19980601)52:5<569::aid-jnr9>;2-a
  58. Igarashi M., Growth cone collapse and inhibition of neurite growth by Botulinum neurotoxin C1: a t-SNARE is involved in axonal growth, 10.1083/jcb.134.1.205
  59. Sonveaux Pierre, Dessy Chantal, Martinive Philippe, Havaux Xavier, Jordan Bénédicte F., Gallez Bernard, Grégoire Vincent, Balligand Jean-Luc, Feron Olivier, Endothelin-1 Is a Critical Mediator of Myogenic Tone in Tumor Arterioles : Implications for Cancer Treatment, 10.1158/0008-5472.can-03-1291
  60. Gallez Bernard, Jordan B�n�dicte F., Baudelet Christine, Misson Pierre-Damien, Pharmacological modifications of the partial pressure of oxygen in murine tumors: Evaluation using in vivo EPR oximetry, 10.1002/(sici)1522-2594(199910)42:4<627::aid-mrm2>;2-m
  61. Gallez Bernard, Baudelet Christine, Jordan Bénédicte F., Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications, 10.1002/nbm.900
  62. Baudelet Christine, Ansiaux Réginald, Jordan Bénédicte F, Havaux Xavier, Macq Benoit, Gallez Bernard, Physiological noise in murine solid tumours using T2*-weighted gradient-echo imaging: a marker of tumour acute hypoxia?, 10.1088/0031-9155/49/15/006
  63. CRON, Proc. Intl. Soc. Mag. Reson. Med, 14, 1764 (2006)
  64. KLEIN, Dermatol. Surg, 29, 549 (2003)
  65. Van Mellaert Lieve, Barbé Sofie, Anné Jozef, Clostridium spores as anti-tumour agents, 10.1016/j.tim.2006.02.002
  66. Minton Nigel P., Mauchline Margaret L., Lemmon Marylin J., Brehm John K., Fox Mary, Michael N. Paul, Giaccia Amato, Brown J. Martin, Chemotherapeutic tumour targeting using clostridial spores, 10.1111/j.1574-6976.1995.tb00219.x
  67. Jordan Bénédicte F, Misson Pierre-Damien, Demeure Roger, Baudelet Christine, Beghein Nelson, Gallez Bernard, Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI, 10.1016/s0360-3016(00)00694-5
  68. ANSIAUX, Clin. Cancer Res, 11, 743 (2005)
  69. Segers Jérome, Fazio Vincent Di, Ansiaux Réginald, Martinive Philippe, Feron Olivier, Wallemacq Pierre, Gallez Bernard, Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: Importance of optimal scheduling to exploit the ‘normalization’ window of the tumor vasculature, 10.1016/j.canlet.2005.12.017
  70. Bussink J, Kaanders J.H.A.M, Rijken P.F.J.W, Peters J.P.W, Hodgkiss R.J, Marres H.A.M, van der Kogel A.J, Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts: effects of carbogen and nicotinamide, 10.1016/s0167-8140(99)00010-9
  71. Baudelet Christine, Gallez Bernard, How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors?, 10.1002/mrm.10318
  72. Kleinberg L., Grossman S.A., Carson K., Lesser G., O’Neill A., Pearlman J., Phillips P., Herman T., Gerber M., Survival of Patients With Newly Diagnosed Glioblastoma Multiforme Treated With RSR13 and Radiotherapy: Results of a Phase II New Approaches to Brain Tumor Therapy CNS Consortium Safety and Efficacy Study, 10.1200/jco.2002.01.096
  73. Hou Huagang, Khan Nadeem, O’Hara Julia A., Grinberg Oleg Y., Dunn Jeff F., Abajian Michelle A., Wilmot Carmen M., Demidenko Eugene, Lu Shiyi, Steffen Robert P., Swartz Harold M., Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study, 10.1016/j.ijrobp.2004.12.077
  74. GODA, Cancer Res, 56, 3344 (1996)
  75. Crokart Nathalie, Jordan Bénédicte F., Baudelet Christine, Ansiaux Reginald, Sonveaux Pierre, Grégoire Vincent, Beghein Nelson, DeWever Julie, Bouzin Caroline, Feron Olivier, Gallez Bernard, Early reoxygenation in tumors after irradiation: Determining factors and consequences for radiotherapy regimens using daily multiple fractions, 10.1016/j.ijrobp.2005.02.038
  76. Cron Greg O., Beghein Nelson, Crokart Nathalie, Chavée Emilie, Bernard Sabine, Vynckier Stefaan, Scalliet Pierre, Gallez Bernard, Changes in the tumor microenvironment during low-dose-rate permanent seed implantation iodine-125 brachytherapy, 10.1016/j.ijrobp.2005.07.971
  77. Biaglow John E, Manevich Yefim, Leeper Dennis, Chance Britton, Dewhirst Mark W, Jenkins Walter T, Tuttle Steve W, Wroblewski Krzysztof, Glickson Jerry D, Stevens Craig, Evans Sydney M, MIBG inhibits respiration: potential for radio- and hyperthermic sensitization, 10.1016/s0360-3016(98)00334-4
  78. JORDAN, Cancer Res, 62, 3555 (2002)
  79. CROKART, Cancer Res, 65, 7911 (2005)
  80. Chaddock J. A., Marks P. M. H., Clostridial neurotoxins: structure-function led design of new therapeutics, 10.1007/s00018-005-5505-5